Milestone Pharmaceuticals Reports Q2 2026 Earnings and Commercial Progress
Milestone Pharmaceuticals (NASDAQ: MIST) reported its second-quarter earnings for 2026, highlighting significant progress in the commercial launch of CARDAMYST. Product revenue reached $559,000 during the quarter, marking a fourfold increase in prescriptions from Q1 and reaching over 800 unique prescribers since February's launch. The company reported cash reserves of $170.6 million as of June 30, 2026, with management projecting sufficient capital to fund operations through the second half of 2027. Despite a net loss of $28.6 million for Q2—up from $13 million in the prior-year period—the company is expanding its commercial insurance coverage and preparing for Medicare coverage starting in 2027. Milestone also outlined regulatory milestones, including an expected decision on etripamil's marketing application by mid-2027. The firm remains focused on addressing a high-value patient population with atrial fibrillation-related rapid ventricular rate (AFib-RVR), targeting up to four million patients in the U.S.
Tickers: $MIST
Topics: cash_position expenses prescriptions revenue